Will Baizean be included in medical insurance in 2022?

The immunotherapy drugs for lung cancer that began to be included in medical insurance in 2022 are as follows: indications of tillizumab (Baizean): 1? Paclitaxel combined with carboplatin as a first-line treatment for unresectable locally advanced or metastatic squamous non-small cell lung cancer. 2? Pemetrexed combined with platinum chemotherapy is the first-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR gene mutation negative and ALK negative and inoperable. 20 18 Up to now, many research data in the field of lung cancer have been published, and combined chemotherapy has been fully approved for locally advanced or metastatic squamous non-small cell lung cancer. The treatment of non-squamous lung cancer was recently approved in June this year, and it was included in medical insurance six months later. At the median follow-up time of 9.8 months, the combination of tillizumab and chemotherapy significantly improved the median disease-free survival time of advanced non-squamous cell lung cancer to 9.7 months, and significantly reduced the risk of disease progression by 36%. The objective remission rate of combined chemotherapy group was 57.4%, which was significantly higher than that of chemotherapy group (36.9%).